These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21481708)

  • 21. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.
    Mitchell DK; Holmes SJ; Burke RL; Duliege AM; Adler SP
    Pediatr Infect Dis J; 2002 Feb; 21(2):133-8. PubMed ID: 11840080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.
    Plotkin SA; Starr SE; Friedman HM; Brayman K; Harris S; Jackson S; Tustin NB; Grossman R; Dafoe D; Barker C
    Ann Intern Med; 1991 Apr; 114(7):525-31. PubMed ID: 1848053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection and pharmacokinetics of a cytomegalovirus (CMV) DNA plasmid in human plasma during a clinical trial of an intramuscular CMV vaccine in hematopoietic stem cell transplant recipients.
    Salimnia H; Fairfax MR; Chandrasekar PH
    Transpl Infect Dis; 2014 Dec; 16(6):914-8. PubMed ID: 25412866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A
    Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C
    Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation.
    Lumley S; Green C; Rafferty H; Smith C; Harber M; O'Beirne J; Jones G; Thorburn D; Marshall A; Shah T; Zuhair M; Rothwell E; Atabani S; Haque T; Griffiths P
    PLoS One; 2019; 14(1):e0210420. PubMed ID: 30682032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cytomegalovirus vaccine tames the troll of transplantation.
    Schleiss MR
    Lancet; 2011 Apr; 377(9773):1216-8. PubMed ID: 21481691
    [No Abstract]   [Full Text] [Related]  

  • 35. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
    Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
    J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial.
    Hibberd PL; Tolkoff-Rubin NE; Conti D; Stuart F; Thistlethwaite JR; Neylan JF; Snydman DR; Freeman R; Lorber MI; Rubin RH
    Ann Intern Med; 1995 Jul; 123(1):18-26. PubMed ID: 7762909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.